Group B streptococcal conjugate vaccine: A timely concept for which the time has come

 Abstract

Invasive disease due to group B Streptococcus (GBS) has been recognized as a threat to the health of pregnant women and their infants for almost half a century. Development of GBS vaccine candidates has progressed at an exemplary pace given lack of manufacturer development, but efficacy testing of candidate GBS conjugate vaccines has been mired in economic and regulatory concerns for longer than a decade. A trivalent or pentavalent vaccine will be required, and decisions must be made as to the criteria by which efficacy will be determined and the population in whom efficacy will be assessed. Concerns regarding durability of conjugate vaccine-derived immunity, pregnant women as a possible target group and regulatory issues required for licensing must be resolved if the prospect of impacting GBS disease burden through immunization is to become a reality.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
444 - 448
doi
10.4161/hv.4.6.6507
Type
Commentary
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Group B streptococcal conjugate vaccine: A timely concept for which the time has come